Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290690 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL26894660 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL26115168 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL7290205 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL22271695 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL22463686 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL15235923 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL26120902 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL8242353 | 1.00 | DGKA (0.52) | DGKALMNAPAMMEN1KMT2A | |
| SCHEMBL2299522 | 0.98 | DGKA (0.48) | DGKALMNAPAMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| WO-2025076243-A1 | CELL-TARGETING COMPLEXES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024137663-A2 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023192830-A2 | MODIFIED OLIGONUCLEOTIDES | EMPIRICO INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192828-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | EMPIRICO INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230304008-A1 | MODIFIED OLIGONUCLEOTIDES | EMPIRICO INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230304008-A1 | MODIFIED OLIGONUCLEOTIDES | EMPIRICO INC. | 2023-09-28 | — | — | US | disclosed |
| EP-2474553-B1 | Compounds for diagnosing apoptosis | GUERBET SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| EP-2474553-A2 | Compounds for diagnosing apoptosis | GUERBET (FR) | 2012-07-11 | — | — | EP | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008125420-A2 | COMPOUNDS FOR DIAGNOSING APOPTOSIS | GUERBET (FR) | 2008-10-23 | — | — | WO | disclosed |
| US-20070292354-A1 | Contrast Agents Encapsulating Systems for Cest Imaging | GUERBET (FR) | 2007-12-20 | — | — | US | disclosed |
| US-20070292354-A1 | Contrast Agents Encapsulating Systems for Cest Imaging | GUERBET (FR) | 2007-12-20 | — | — | US | disclosed |
| US-6762169-B1 | IMPROVED TRANSMEMBRANE DELIVERY OF NUCLEOSIDES CONJUGATED TO AN ARYLPROPIONIC ACID LIGAND (IBUPROFEN) WHICH HAS AFFINITY FOR PLASMA PROTEIN ALBUMIN; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6656730-B1 | Attached to an arylpropionic acid that interacts with human serum albumin; acid is ibuprofen, suprofen, ketoprofen, (S)-(+)- pranoprofen, or carprofen. | ISIS PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1185305-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0447186-A1 | N-acylated cyclohexapeptide compounds | MERCK & CO. INC. (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | TPX2, VIP, BAX | DGKA 1053/4885LMNA 631/4885PAM 2651/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | DGKA 2128/4885LMNA 4711/4885PAM 3705/4885 |
| US-20070292354-A1 | Contrast Agents Encapsulating Systems for Cest Imaging | SLC46A1, CEPT1, MPST | DGKA 2498/4885LMNA 1284/4885PAM 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.